111 related articles for article (PubMed ID: 21199824)
1. The risks to healthy tissues from the use of existing and emerging techniques for radiation therapy.
Ottolenghi A; Smyth V; Trott KR
Radiat Prot Dosimetry; 2011 Feb; 143(2-4):533-5. PubMed ID: 21199824
[TBL] [Abstract][Full Text] [Related]
2. Risks to normal tissues from radionuclide therapy.
Meredith R; Wessels B; Knox S
Semin Nucl Med; 2008 Sep; 38(5):347-57. PubMed ID: 18662556
[TBL] [Abstract][Full Text] [Related]
3. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiation therapy, protons, and the risk of second cancers.
Hall EJ
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):1-7. PubMed ID: 16618572
[TBL] [Abstract][Full Text] [Related]
5. Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy.
Fiorino C; Dell'Oca I; Pierelli A; Broggi S; De Martin E; Di Muzio N; Longobardi B; Fazio F; Calandrino R
Radiother Oncol; 2006 Mar; 78(3):276-82. PubMed ID: 16546279
[TBL] [Abstract][Full Text] [Related]
6. Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts.
Nieder C; Schill S; Kneschaurek P; Molls M
Radiother Oncol; 2007 Mar; 82(3):301-7. PubMed ID: 17156873
[TBL] [Abstract][Full Text] [Related]
7. Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma.
Ahmed M; Hansen VN; Harrington KJ; Nutting CM
Med Dosim; 2009; 34(3):217-24. PubMed ID: 19647632
[TBL] [Abstract][Full Text] [Related]
8. Measurements of secondary neutron dose from 15 MV and 18 MV IMRT.
Howell RM; Ferenci MS; Hertel NE; Fullerton GD; Fox T; Davis LW
Radiat Prot Dosimetry; 2005; 115(1-4):508-12. PubMed ID: 16381776
[TBL] [Abstract][Full Text] [Related]
9. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
[TBL] [Abstract][Full Text] [Related]
10. Technical and dosimetric considerations in multi-isocenter intensity modulated radiotherapy for nasopharyngeal carcinoma with small multileaf collimator.
Xiance J; Shixiu W; Jianyi Y; Jinling Y
Med Dosim; 2009; 34(1):9-15. PubMed ID: 19181249
[TBL] [Abstract][Full Text] [Related]
11. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh.
Hong L; Alektiar KM; Hunt M; Venkatraman E; Leibel SA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):752-9. PubMed ID: 15183478
[TBL] [Abstract][Full Text] [Related]
13. Radiation and your patient: a guide for medical practitioners.
Ann ICRP; 2001; 31(4):5-31. PubMed ID: 12685757
[TBL] [Abstract][Full Text] [Related]
14. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas.
Kozak KR; Adams J; Krejcarek SJ; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):179-86. PubMed ID: 19019562
[TBL] [Abstract][Full Text] [Related]
15. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
16. Protecting people against radiation exposure in the event of a radiological attack. A report of The International Commission on Radiological Protection.
Valentin J;
Ann ICRP; 2005; 35(1):1-110, iii-iv. PubMed ID: 16164984
[TBL] [Abstract][Full Text] [Related]
17. [Radiation effect in normal tissue - principles of damage and protection].
Dörr W
Nuklearmedizin; 2010; 49 Suppl 1():S53-8. PubMed ID: 21152682
[TBL] [Abstract][Full Text] [Related]
18. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors.
Palm A; Johansson KA
Acta Oncol; 2007; 46(4):462-73. PubMed ID: 17497313
[TBL] [Abstract][Full Text] [Related]
19. Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?
Vanneste BG; Van Limbergen EJ; van Lin EN; van Roermund JG; Lambin P
Biomed Res Int; 2016; 2016():6829875. PubMed ID: 28116302
[TBL] [Abstract][Full Text] [Related]
20. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio.
Hille A; Töws N; Schmidberger H; Hess CF
Strahlenther Onkol; 2005 Dec; 181(12):789-95. PubMed ID: 16362789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
